Over the past decade, the Tactical Assault Kit (TAK) has grown from a research experiment into one of the most widely used ...
Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback